|
 Data showed that the durability of immune response for recipients of
its vaccine lasted at least eight months, the healthcare company
said, adding that its vaccine was 85% effective and could also help
prevent hospitalization and death.
First identified in India, Delta is becoming the globally dominant
variant of the coronavirus, according to the World Health
Organization.
"Current data for the eight months studied so far shows that the
single-shot Johnson & Johnson COVID-19 vaccine generates a strong
neutralizing antibody response that does not wane; rather, we
observe an improvement over time," Mathai Mammen, head of research &
development at J&J's drugs business, said in the statement.
Recipients of the vaccine produced strong neutralizing antibodies
against all variants including the Delta, the U.S.-based company
said.
[to top of second column] |
 The Delta variant contributed
to a surge in COVID-19 cases in India that
resulted in the highest daily death tally in the
world, and also prompted the UK to delay its
reopening by one month in June.
J&J has submitted data as a preprint to the
website bioRxiv ahead of peer review.
Other vaccine makers including Pfizer-BioNTech,
Moderna Inc, and AstraZeneca Plc have previously
said that their COVID-19 vaccines are effective
against the fast-spreading Delta..
(Reporting by Aakriti Bhalla in Bengaluru,
Editing by Sherry Jacob-Phillips)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
